ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2026
FAK Mediated Coordination of Extracellular Matrix Remodeling and Cellular Mechanics Impairs Nanomedicine Delivery in Solid Tumors.
Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
Tumor extracellular matrix (ECM) remodeling and cell-intrinsic mechanical properties critically limit nanoparticle (NP) delivery, yet how these multiscale biophysical cues are coordinately regulated remains unclear. Here, we identify focal adhesion kinase (FAK/PTK2) as a central mechanobiological regulator that couples ECM remodeling with cellular mechanics to control NP transport and cellular uptake. The ECM derived from patients' tumors exhibited increased stiffness and collagen density, which severely restricted NP penetration, while PTK2 emerged as a key integrin-associated signaling hub linked to ECM organization. FAK depletion or inhibition disrupted ECM homeostasis, significantly enhanced NP penetration and cellular uptake. Mechanistically, FAK loss reduced cellular stiffness and cytoskeletal tension while increasing membrane deformability and transcriptionally reprogramming endocytic pathways, with clathrin-mediated endocytosis as the dominant route. In vivo, FAK ablation remodeled the tumor stroma to enhance NP accumulation and penetration, and the combination of FAK inhibition with chemotherapy demonstrated potent antitumor efficacy. Together, these results establish a multiscale mechanistic paradigm in which FAK integrates ECM biophysics, cellular mechanics, and endocytic regulation to gatekeep nanomedicine delivery. Targeting FAK offers a potential strategy to enhance therapeutic penetration and efficacy in solid tumors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.